OmniActive screened 42 botanicals to identify the most promising solutions for women navigating perimenopause and menopause. Although shatavari is an emerging women’s health botanical, OmniActive did not want to develop another standalone ingredient for an increasingly crowded market. By identifying the complementary biology of shatavari and fenugreek, the company developed Fenavari to deliver a synergistic, multi-pathway support for women throughout perimenopause and menopause. Women taking either a 300 mg or 500 mg dose experienced a decrease in menopause symptoms as early as day 14 of supplementation. “Dose-Dependent Efficacy of a Combined Standardized Extract of Fenugreek and Shatavari on Menopausal Symptoms: A Randomized, Double-Blind, Parallel, Placebo-Controlled Study.”